STOCK TITAN

Generation Bio Co. - GBIO STOCK NEWS

Welcome to our dedicated page for Generation Bio Co. news (Ticker: GBIO), a resource for investors and traders seeking the latest updates and insights on Generation Bio Co. stock.

Generation Bio Co. (Nasdaq: GBIO) is a pioneering biotechnology company dedicated to developing innovative genetic medicines to treat rare and prevalent diseases. The company's mission is to deliver durable and redosable treatments through their groundbreaking platforms. Generation Bio focuses on liver and retina-related diseases and has built a robust pipeline leveraging two main proprietary technologies: the cell-targeted lipid nanoparticle (ctLNP) delivery system and immune-quiet DNA (iqDNA) cargo.

Using the ctLNP delivery system, Generation Bio can selectively target specific tissues and cell types, significantly reducing off-target effects. This system has shown promising results in both mouse models and non-human primates (NHPs), demonstrating effective delivery of genetic materials with minimal immunogenic response. The ctLNP platform is a cornerstone of their collaborative efforts with Moderna, aimed at developing highly specific in vivo delivery systems for T cells and other immune cells.

iqDNA, an optimized variant of the company's closed-ended DNA (ceDNA), stands out for its ability to evade the immune system while maintaining high levels of gene expression. This feature addresses a critical challenge in genetic therapies by allowing for repeated dosing without triggering adverse immune responses. Recent studies have shown that iqDNA has a tolerability profile comparable to chemically modified messenger RNA (mRNA) in both mice and NHPs.

Generation Bio's commitment to innovation is further highlighted by their rapid enzymatic synthesis (RES) manufacturing process. This proprietary method enables scalable and efficient production of their novel DNA constructs, ensuring high purity and consistency. The company believes that RES can support the manufacturing scale required to meet global clinical and commercial demands.

Recent announcements have emphasized the company's progress and strategic collaborations. For instance, their partnership with Moderna focuses on leveraging ctLNPs for targeted delivery of nucleic acid therapies to specific immune cell types. Additionally, Generation Bio's sustained financial health, supported by careful expense management and collaboration incomes, ensures a steady runway into 2026, enabling continued investment in their groundbreaking technologies.

On the business front, Generation Bio is ramping up efforts across their platforms, with ongoing programs targeting hemophilia A, sickle cell disease, and beta-thalassemia. The company is actively presenting their latest data at key industry conferences like the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, showcasing the advanced capabilities of their ctLNP and iqDNA platforms.

For more information about Generation Bio’s revolutionary work in genetic medicine, please visit their website at www.generationbio.com or follow their updates on Twitter (@lifetimegenetx).

Rhea-AI Summary
Generation Bio Co. (GBIO) reports progress in developing cell-targeted lipid nanoparticle delivery for sickle cell disease and beta-thalassemia, alongside advancements in immune-quiet DNA for hemophilia A. The company's cash balance of $264.4 million is expected to sustain operations till the second half of 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.5%
Tags
-
Rhea-AI Summary
Generation Bio Co. (GBIO) CEO to present at 2024 TD Cowen Health Care Conference, offering a live webcast for investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.79%
Tags
conferences
-
Rhea-AI Summary
Generation Bio Co. (Nasdaq:GBIO) announced that Geoff McDonough, M.D., will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024, to discuss the company's genetic medicines for rare and prevalent diseases. A live webcast and replay will be available on the investor section of the company’s website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.6%
Tags
conferences
Rhea-AI Summary
Generation Bio Co. (Nasdaq:GBIO) announced a strategic reorganization to prioritize investment in the development of its cell-targeted lipid nanoparticle (ctLNP) delivery system for wholly-owned programs in extrahepatic cell types. The company also intends to continue developing ctLNP for immune cells as part of its collaboration with Moderna and to develop its immune-quiet DNA (iqDNA) for its lead hemophilia A program and other programs. This strategic move will result in a 40% reduction of the workforce, but it is anticipated to extend the cash runway into the second half of 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
none
-
Rhea-AI Summary
Generation Bio Co. (Nasdaq: GBIO) reported business highlights and third quarter 2023 financial results, including a cash balance of $291.0 million expected to fund operations into 2026. The company announced breakthroughs in genetic medicine with immune-quiet DNA (iqDNA) evading innate immune sensors in mice and non-human primates, and a proprietary cell-targeted lipid nanoparticle (ctLNP) delivery system showing highly selective T cell transduction in a humanized mouse model.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.58%
Tags
-
Rhea-AI Summary
Generation Bio announces significant achievements in in vivo studies, demonstrating selective T cell targeting with its ctLNP platform and confirming stealth properties in non-human primates. The data show the potential for in vivo delivery to T cells and extrahepatic tissues.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
none
Rhea-AI Summary
Generation Bio announces the development of immune-quiet DNA (iqDNA), a novel variant of closed-ended DNA (ceDNA) that evades host innate immune detection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.51%
Tags
none
-
Rhea-AI Summary
Generation Bio CEO to participate in fireside chat at Jefferies Cell & Genetic Medicine Summit
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
conferences
-
Rhea-AI Summary
Generation Bio Co. (Nasdaq:GBIO) will present at the 2023 Canaccord Healthcare Conference on August 10, 2023. The presentation will be given by Matt Norkunas, M.D., the company's chief financial officer. The event will take place in Boston at 11:00 a.m. ET and will be live-streamed on the investor section of the company's website. A replay of the presentation will be available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags
conferences
Rhea-AI Summary
Generation Bio reports second quarter 2023 financial results with a cash balance of $314.1 million expected to fund operations into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags

FAQ

What is the current stock price of Generation Bio Co. (GBIO)?

The current stock price of Generation Bio Co. (GBIO) is $1.19 as of December 20, 2024.

What is the market cap of Generation Bio Co. (GBIO)?

The market cap of Generation Bio Co. (GBIO) is approximately 72.1M.

What does Generation Bio Co. specialize in?

Generation Bio Co. specializes in developing innovative genetic medicines designed to provide durable, redosable treatments for rare and prevalent diseases.

What are the core technologies of Generation Bio?

The core technologies of Generation Bio include the cell-targeted lipid nanoparticle (ctLNP) delivery system and immune-quiet DNA (iqDNA) cargo.

What is iqDNA?

iqDNA is an optimized variant of closed-ended DNA (ceDNA) designed to evade the immune system while maintaining high levels of gene expression, allowing for repeated dosing.

What is the ctLNP delivery system?

The ctLNP delivery system is a potent, highly selective method for delivering genetic materials to specific tissues and cell types, reducing off-target effects and improving therapeutic efficacy.

How does Generation Bio’s rapid enzymatic synthesis (RES) process work?

The RES process is a proprietary cell-free method that enables scalable and efficient production of novel DNA constructs, ensuring high purity and consistency.

Who are Generation Bio’s strategic partners?

Generation Bio has a notable collaboration with Moderna, focusing on developing in vivo delivery systems for nucleic acid therapies targeting specific immune cell types.

What diseases are Generation Bio targeting with their therapies?

Generation Bio is targeting diseases such as hemophilia A, sickle cell disease, and beta-thalassemia with their genetic medicine platforms.

What is the financial outlook for Generation Bio?

Generation Bio has extended their cash runway into 2026, supported by careful expense management and collaboration income, allowing continued investment in their technologies.

Where can I find more information about Generation Bio?

More information about Generation Bio can be found on their official website at www.generationbio.com and their Twitter feed @lifetimegenetx.

What recent advancements has Generation Bio made?

Recent advancements include the development of iqDNA, a novel immune-quiet DNA, and the ctLNP delivery system, showcased at key industry conferences such as the ASGCT Annual Meeting.

Generation Bio Co.

Nasdaq:GBIO

GBIO Rankings

GBIO Stock Data

72.14M
57.09M
14.51%
83.88%
2.22%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CAMBRIDGE